

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/003999 A1

(51) International Patent Classification:

A61K 39/39 (2006.01) A61K 47/10 (2006.01)
A61K 9/107 (2006.01) A61K 47/14 (2006.01)
A61K 39/015 (2006.01) A61K 47/22 (2006.01)
A61K 47/06 (2006.01) A61K 47/26 (2006.01)

(21) International Application Number:

PCT/JP2020/044675

(22) International Filing Date:

01 December 2020 (01.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/045,540 29 June 2020 (29.06.2020) US

(71) Applicants: **PATH** [US/US]; 2201 Westlake Avenue, Suite 200, Seattle, Washington, 98121 (US). **SUMITOMO DAINIPPON PHARMA CO., LTD.** [JP/JP]; 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, 5418524 (JP).

(72) Inventors; and

(71) Applicants: **THEISEN, Michael** [DK/DK]; Artillerivej 5, 2300 Copenhagen S (DK). **SINGH, Susheel Kumar** [DK/DK]; Nedertofte 31, 1TV, Vanlose, 2720 Copenhagen (DK).

(72) Inventors: **KING, C. Richter**; 1840 Park Road NW, Washington, District of Columbia, 20010 (US). **WU, Yimin**; 18133 Coachmans Road, Germantown, Maryland, 20874 (US). **PLIESKATT, Lee Jordan**; 624 N Columbus Street Alexandria, Virginia, 22314 (US). **FUKUSHIMA, Aki-hisa**; c/o Sumitomo Dainippon Pharma Co., Ltd., 1-98,

Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP).

(74) Agent: **YAMAO, Norihito** et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kaku-da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PRE-ERYTHROCYTIC MALARIA VACCINES

[Fig. 1]



(57) Abstract: Pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[(4-[(2-amino-4-[(3S)-1-hydroxyhexan-3-yl]amino)-6-methylpyrimidin-5-yl)methyl]benzyl] (methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosan-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with biological activity allow for the provision of pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action.

WO 2022/003999 A1